7th June 2023 — F2G and Shionogi have made the difficult decision to temporarily close the olorofim managed access programme (MAP) to new patients effective immediately. Drug supply will continue for all patients who have been approved for access.
Demand for olorofim has been unprecedented and significantly exceeded our forecast expectations. To be able to meet demand moving forward, and to ensure we meet our commitments to those patients who are already benefitting from olorofim, we need to temporarily pause access to new patients while we move new supplies of olorofim into the supply chain.
We know that this will be disappointing for many and will create challenges with regards to patient management. Please be rest assured we are doing everything we can to ensure that the MAP is closed for the shortest time possible.
If you have a patient who is already receiving olorofim via the MAP, please continue to place orders for resupply as usual.
We will continue to provide updates with regards to timing for reopening the MAP. At this time, we anticipate the MAP will be closed to new patients for a minimum of 6 weeks. Please direct any questions to medinfo@f2g.com.